Jafron Biomedical Co.,Ltd. (SHE:300529)

China · Delayed Price · Currency is CNY

17.09

+0.54 (3.26%)

Jul 15, 2026, 11:54 AM CST

-24.41% (1Y)

Market Cap	12.82B -21.8%
Revenue (ttm)	2.02B -18.4%
Net Income	564.55M -22.0%
EPS	0.74 -20.0%
Shares Out	774.36M
PE Ratio	22.39
Forward PE	20.31
Dividend	0.52 (3.20%)
Ex-Dividend Date	Jun 1, 2026

Volume	7,760,848
Open	15.84
Previous Close	16.55
Day's Range	15.84 - 17.13
52-Week Range	14.73 - 24.98
Beta	0.44
Analysts	Strong Buy
Price Target	24.12 (+41.14%)
Earnings Date	Aug 7, 2026

About Jafron Biomedical

Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification machine; and other products, such as JM hemodialyzer, DNA230, disinfectant, hemodialysis concentrate, resin bandage, online hemodialysis B powder bag/bucket... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 1989

Employees 2,301

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 300529

Full Company Profile

Financial Performance

In 2025, Jafron Biomedical's revenue was 2.01 billion, a decrease of -24.86% compared to the previous year's 2.68 billion. Earnings were 532.82 million, a decrease of -35.04%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 300529 stock is "Strong Buy." The 12-month stock price target is ¥24.12, which is an increase of 41.14% from the latest price.

Price Target

¥24.12

(41.14% upside)

Analyst Consensus: Strong Buy

Stock Forecasts